Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 22,285 shares, a decline of 97.9% from the June 15th total of 1,073,474 shares. Based on an average trading volume of 3,128 shares, the short-interest ratio is presently 7.1 days.

Innovent Biologics Price Performance

Shares of IVBXF stock traded up $0.05 during mid-day trading on Friday, reaching $11.39. The stock had a trading volume of 1,162 shares, compared to its average volume of 4,527. The firm’s 50 day simple moving average is $10.36 and its 200 day simple moving average is $10.60. Innovent Biologics has a one year low of $9.10 and a one year high of $15.12.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).